DDI2 and plasma cell myeloma: Recognizing the potential importance of DDI2 in the context of proteasome inhibitor therapy in cancer treatment, we also investigated the effect of DDI2 KO in the myeloma cell line U266B, which was shown to be sensitive to the first generation of proteasome inhibitors (Hideshima et al., 2001).